期刊文献+

中老年CD-1小鼠海马Staufen蛋白含量改变及其与认知功能减退的相关性研究 被引量:1

Changed Staufen level of hippocampus correlates with the impaired spatial learning and memory in the middle-aged CD-1 mice
下载PDF
导出
摘要 探讨中老年CD-1小鼠海马Staufen(Stau)蛋白含量的改变及其与空间学习记忆功能减退之间的相关性。选取3月龄(青年)和15月龄(中老年)CD-1小鼠各10只(雌雄各半)。采用Morris水迷宫评估空间学习记忆能力,用免疫组织化学技术检测海马Stau蛋白的相对含量。结果发现,与3月龄小鼠相比,15月龄鼠在Morris水迷宫中学习期游泳路程显著延长(P<0.01),记忆期靶象限游泳路程百分比显著降低(P<0.05),且海马CA1区和CA3区Stau蛋白含量显著升高(P<0.05)。相关性分析显示,15月龄小鼠CA1区、CA3区Stau蛋白含量与学习期游泳路程呈正相关(P<0.05),CA3区Stau蛋白含量与记忆期靶象限路程百分比呈负相关(P<0.05)。以上结果提示中老年CD-1小鼠海马Stau蛋白含量呈亚区特异性增加,且可能与海马相关性空间学习记忆的损害有关。 To investigate whether the changed level of Staufen(Stau) protein exists in the hippocampus of middle-aged CD-1 mice, and if this is case, whether it is correlated with impairment of spatial learning and memory, 3-month(young) and 15-month(middle-aged) CD-1 mice were used(5 males and 5 females per group) to evaluate the ability of spatial learning and memory using Morris water maze test, and the expression of Stau protein was examined using immunohistochemical method. The results showed that compared to the 3-month mice,the 15-month mice had significantly longer swimming distance during the learning phase(P<0.01) and lower percentage of distance in the target quadrant during the memory phase(P<0.05) in the Morris water maze. The15-month mice showed significantly higher level of Stau protein in the hippocampal CA1 and CA3 subregions(P<0.05). Correlation analysis indicated that the Stau level in the CA1 and CA3 negatively correlated with the learning swimming distance(P<0.05), while the protein level in the CA3 positively correlated with the memory percentage of distance in the target quadrant in the 15-month mice(P<0.05). These results suggested that the Stau protein content in hippocampus increased in a subareas-dependent manner in the middle-aged CD-1 mice, and this increment was associated with the impaired spatial learning and memory.
作者 吴永芳 徐劲 张折折 李学伟 曹磊 陈贵海 WU Yongfang;XU Jin;ZHANG Zhezhe;LI Xuewei;CAO Lei;CHEN Guihai(Department of Neurology (Sleep Disorders),the Affiliated Chaohu Hospital of Anhui Medical University,Hefei 238000;Department of Neurology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022;Department of Neurology,the First Affiliated Hospital of Nanhua University,Hengyang 421001;Department of Neurology,the Second Affiliated Hospital of Anhui Medical University,Hefei 230601)
出处 《安徽农业大学学报》 CAS CSCD 2019年第2期219-223,共5页 Journal of Anhui Agricultural University
基金 国家自然科学基金(81370444,81671316) 安徽省青年自然科学基金(1708085QH182)共同资助
关键词 衰老 海马 学习记忆 Stau蛋白 aging hippocampus learning and memory Staufen protein
  • 相关文献

参考文献2

二级参考文献16

  • 1Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease[J]. J Clin Invest, 2005, 115(5):1121-1129.
  • 2Hardy J, Selkoe D J. The amyloid hypothesis of Alz- heimer's disease: progress and problems on the road to therapeutics[J]. Science, 2002, 297(5590):353-356.
  • 3Naslund J, Haroutunian V, Mohs R, et al. Correlation be- tween elevated levels of amyloid beta-peptide in the brain and cognitive decline[J]. J Am Med Assoc, 2000, 283(12): 1571-1577.
  • 4Orner B P, Liu L, Murphy R M, et al. Phage display af- fords peptides that modulate beta-amyloid aggregation[J]. JAMA, 2006, 128(36):11882-11889.
  • 5Yamaguchi Y, Kawashima S. Effects of amyloid-beta-25- 35 on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat[J]. Euro J Pharmacol, 2001, 412 (3):265-272.
  • 6Wang R, Zhang H Y, Tang X C. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta amyloid protein-(1-40) in rat[J]. Eur J Pharmacol, 2001, 421(3): 149-156.
  • 7Gauthier S, Scheltens P. Can we do better in developing new drugs for Alzheimer's disease?[J]. Alzheimers Dement, 2009, 5(6): 489-491.
  • 8Bharadwaj P R, Dubey A K, Masters C L, et al. Abeta ag- gregation and possible implications in Alzheimer's disease pathogenesis[J]. J Cell Mol Med, 2009, 13(3): 412-421.
  • 9Creed M C, Milgram N W. Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its im- plications[J]. Age (Dordr), 2010, 32(3): 365-384.
  • 10Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended[J]. Lancet Neurol, 2002, 1(1): 3.

共引文献1

同被引文献1

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部